Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RDHL with free AI briefings, catalyst countdowns, and dilution alerts.

RDHL · RedHill Biopharma Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$5.2M Cash on Hand
8mo Cash Runway
Follow RDHL by email Get an email when RDHL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RDHL, unsubscribe in one click. Privacy

📣 What RDHL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
RHB-204 Pulmonary Mycobacterium Avium Complex Infection Phase 3 · NCT04616924 Terminated
RHB-105 Helicobacter Pylori Infection Phase 3 · NCT03198507 Completed
RHB-104 (fixed-dose combination: 95 mg… Crohn Disease Phase 3 · NCT03009396 Completed
RHB-104 Crohn's Disease Phase 3 · NCT01951326 Completed
RHB-102 Gastroenteritis Phase 3 · NCT02246439 Completed
Part B: Upamostat 200 or 400 mg Covid19 Phase 2/3 · NCT04723537 Terminated
Part A: Upamostat 200 mg Covid19 Phase 2/3 · NCT04723537 Terminated
Opaganib (ABC294640) COVID-19 Phase 2/3 · NCT04467840 Completed
BEKINDA Irritable Bowel Syndrome With Diarrhea Phase 2 · NCT02757105 Completed
Rifamycin SV MMX Traveler's Diarrhea Phase 2 · NCT04027894 Unknown
Rifamycin SV-MMX Traveler's Diarrhea Phase 2 · NCT04026984 Unknown
Upamostat SARS-CoV-2 Phase 2 · NCT05954286 Completed
sphingosine kinase-2 inhibitor ABC294640 Pancreatic Cancer Phase 1 · NCT01488513 Completed

Also used in these trials (approved or third-party drugs, not RDHL's own candidates): Amoxicillin, Hydroxychloroquine Sulfate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RDHL holds $5.2M in cash and short-term investments and burns about $1.9M/quarter from operations, an estimated runway of 8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 75 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RDHL files for a raise →

👥 Who Owns RDHL

Insiders 4.4% Institutions (15 holders) 3.5% Public and other holders 92.1%
HolderTypeShares% of sharesAs of
Dror Ben-Asher
Chief Executive Officer, Director
Insider 441,350,000 0.87% 2026-03-18
Rick D Scruggs
Chief Commercial Officer, Director
Insider 312,500,000 0.61% 2026-03-18
Guy Joel Goldberg
Chief Business Officer
Insider 305,720,000 0.60% 2026-03-18
Razi Ingber
Chief Financial Officer
Insider 277,560,000 0.55% 2026-03-18
Adi Frish
Chief Corp & BD Officer
Insider 276,810,000 0.54% 2026-03-18
Gilead Raday
Chief Operating Officer · +235.82M options
Insider 176,910,000 0.35% 2026-10-01
Ofer Tsimchi
Director
Insider 146,250,000 0.29% 2026-03-18
Shmuel Cabilly
Director
Insider 105,200,000 0.21% 2026-03-18
Kenneth Reed
Director
Insider 105,200,000 0.21% 2026-03-18
Roni Mamluk
Director
Insider 103,500,000 0.20% 2026-03-18
YA II PN, Ltd. 5%+ holder (13G) 508,723 0.00% 2025-12-19

Share count 50,923,261,000 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full RDHL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RDHL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.